Page 125 - Read Online

Page 28 Melnik et al. J Transl Genet Genom 2022;6:1-45 https://dx.doi.org/10.20517/jtgg.2021.37

directly and indirectly targeting DNA methyltransferase 1. J Immunol 2010;184:6773-81. DOI PubMed
110. Yang A, Sun Y, Gao Y, et al. Reciprocal regulation between miR-148a/152 and DNA methyltransferase 1 is associated with
hyperhomocysteinemia-accelerated atherosclerosis. DNA Cell Biol 2017;36:462-74. DOI PubMed
111. Kuroda A, Rauch TA, Todorov I, et al. Insulin gene expression is regulated by DNA methylation. PLoS One 2009;4:e6953. DOI
PubMed PMC
112. Ouni M, Gunes Y, Belot MP, Castell AL, Fradin D, Bougnères P. The IGF1 P2 promoter is an epigenetic QTL for circulating IGF1
and human growth. Clin Epigenetics 2015;7:22. DOI PubMed PMC
113. Ouni M, Castell AL, Rothenbuhler A, Linglart A, Bougnères P. Higher methylation of the IGF1 P2 promoter is associated with
idiopathic short stature. Clin Endocrinol (Oxf) 2016;84:216-21. DOI PubMed
114. Chen J, Ying Y, Zhu H, et al. Curcumin-induced promoter hypermethylation of the mammalian target of rapamycin gene in multiple
myeloma cells. Oncol Lett 2019;17:1108-14. DOI PubMed PMC
115. Rock CL. Milk and the risk and progression of cancer. Nestle Nutr Workshop Ser Pediatr Program 2011;67:173-85. DOI PubMed
116. Manuelian CL, Penasa M, Visentin G, Zidi A, Cassandro M, De Marchi M. Mineral composition of cow milk from multibreed herds.
Anim Sci J 2018;89:1622-7. DOI PubMed
117. Chan JM, Stampfer MJ, Ma J, Gann PH, Gaziano JM, Giovannucci EL. Dairy products, calcium, and prostate cancer risk in the
Physicians' Health Study. Am J Clin Nutr 2001;74:549-54. DOI PubMed
118. Gao X, LaValley MP, Tucker KL. Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis.
J Natl Cancer Inst 2005;97:1768-77. DOI PubMed
119. Rodriguez C, McCullough ML, Mondul AM, et al. Calcium, dairy products, and risk of prostate cancer in a prospective cohort of
United States men. Cancer Epidemiol Biomarkers Prev 2003;12:597-603. PubMed
120. Hayes RB, Ziegler RG, Gridley G, et al. Dietary factors and risks for prostate cancer among blacks and whites in the United States.
Cancer Epidemiol Biomarkers Prev 1999;8:25-34. PubMed
121. Berndt SI, Carter H, Landis PK, et al. Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal
Study of Aging. Urology 2002;60:1118-23. DOI PubMed
122. Aune D, Navarro Rosenblatt DA, Chan DS, et al. Dairy products, calcium, and prostate cancer risk: a systematic review and meta-
analysis of cohort studies. Am J Clin Nutr 2015;101:87-117. DOI PubMed
123. Maly IV, Hofmann WA. Fatty acids and calcium regulation in prostate cancer. Nutrients 2018;10:788. DOI PubMed PMC
124. Maly IV, Hofmann WA. Calcium and nuclear signaling in prostate cancer. Int J Mol Sci 2018;19:1237. DOI PubMed PMC
125. Harrison S, Lennon R, Holly J, et al. Does milk intake promote prostate cancer initiation or progression via effects on insulin-like
growth factors (IGFs)? Cancer Causes Control 2017;28:497-528. DOI PubMed PMC
126. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to
prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;76:1115-8. DOI PubMed PMC
127. Cohen P, Peehl DM, Rosenfeld R. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J
Cancer 1998;78:554-6. DOI PubMed PMC
128. Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control
study. J Natl Cancer Inst 1998;90:911-5. DOI PubMed
129. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. The insulin-like growth factor axis and prostate cancer: lessons from the
transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 1999;59:2203-9. PubMed
130. Giovannucci E. Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm Res 1999;51 Suppl 3:34-41. DOI
PubMed
131. Kaaks R, Lukanova A, Sommersberg B. Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review. Prostate
Cancer Prostatic Dis 2000;3:157-72. DOI PubMed
132. Chokkalingam AP, Pollak M, Fillmore CM, et al. Insulin-like growth factors and prostate cancer: a population-based case-control
study in China. Cancer Epidemiol Biomarkers Prev 2001;10:421-7. PubMed
133. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer
models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor
(IGF-IR). Cancer Res 2001;61:6276-80. PubMed
134. Shi R, Berkel HJ, Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer 2001;85:991-6. DOI PubMed
PMC
135. Woodson K, Tangrea JA, Pollak M, et al. Serum insulin-like growth factor I: tumor marker or etiologic factor? Cancer Res
2003;63:3991-4. PubMed
136. Roberts CT. IGF-1 and prostate cancer. IGF-1 and prostate cancer. Novartis Found Symp 2004;262:193-9. PubMed
137. Renehan AG, Zwahlen M, Minder C, O'dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3,
and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53. DOI PubMed
138. Krueckl SL, Sikes RA, Edlund NM, et al. Increased insulin-like growth factor I receptor expression and signaling are components of
androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004;64:8620-9. DOI
PubMed
139. Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, Kaaks R. High levels of circulating insulin-like growth factor-I increase
prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 2004;22:3104-12. DOI PubMed
140. Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor-1 and binding
protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 2005;16:255-62. DOI PubMed